GnRH agonists: risk of major CV events incurring increased costs
- PDF / 151,424 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 30 Downloads / 172 Views
1
GnRH agonists: risk of major CV events incurring increased costs Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) [LHRH] receptor agonists increases the risk of major cardiovascular (CV) events in patients with prostate cancer, which leads to increased healthcare costs due to hospitalisation. These were the findings of a Myovant Sciences-funded study presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research in November 2020, which was held as a virtual conference (Virtual ISPOR Europe 2020). Data from the US Marketscan Commercial and Medicare Supplemental Database (2009–2018) were used to investigate the incidence of major adverse cardiovascular events (MACE; including myocardial infarction, stroke, unstable angina, percutaneous coronary intervention and/or coronary artery bypass graft) in men with prostate cancer who had an ADT claim. The frequency of hospitalisation within 30 days after MACE, and MACE-related costs were also assessed. During the study period, MACE was reported in 16.5% of the 49 155 patients receiving ADT for prostate cancer; 6754 of these patients qualified for the post-MACE analysis. Overall, 46.6% of patients with MACE who had Medicare coverage and 45.1% of those with commercial insurance experienced MACE-related hospitalisation within 30 days, and incurred inpatient costs of $36 185* and $55 322, respectively. "ADTs that lower CV risk have the potential to improve patient outcomes while reducing healthcare costs," concluded the authors. * 2018 US dollars Brady B, et al. Major Adverse Cardiovascular Event Hospitalization Burden in Patients with Prostate Cancer (PC) Receiving Androgen Deprivation Therapy (ADT) in the 803519986 United States. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN100, 16 Nov 2020.
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
